The instruction for medical use
of TSITOL® medicine
the Trade name
the International unlicensed
name Tsitalopram Lekarstvennaya
the Tablet form, film coated, 20 mg
One tablet contains
active agent – a tsitaloprama hydrobromide of 24.98 mg
(20 mg of a tsitalopram),
excipients are equivalent: corn starch, the lactose granulated, K-90 polyvinylpirrolidone, microcrystalline PH 200 cellulose, magnesium stearate,
structure of a cover: hydroksipropilmetiltsellyuloza, polyethyleneglycol 400, titan E171 dioxide, deonizirovanny water.
White tablets, oblong, elliptic shape, film coated, with the AI logo on one party and risky on another
Serotonin of the return capture inhibitors selection.
The code of automatic telephone exchange N06AB04
Pharmacokinetics Bioavailability properties at intake makes about 80% and does not depend on meal. The maximum concentration in blood plasma is reached in 2-4 hours after reception. Linking with proteins of plasma – 80%. Metabolism is carried out by demethylation, deamination and oxidation. Not changed tsitalopra is the main connection in blood plasma, its kinetics is linear. Constant concentration in plasma is established in 1-2 weeks of treatment. Elimination half-life of drug makes 1.5 days. Removal is carried out with urine and a stake.
Antidepressant, selective serotonin reuptake inhibitor. The mechanism of action is connected with the significant selection blockade of the return neuronalny serotonin reuptake in IICNS (it is central to nervous system) with the minimum effect concerning the return capture of noradrenaline and dopamine. Does not interact or has very weak ability to contact with directly serotaninovy 5HT1A/2A receptors, selectively taking serotoninovy mediators, does not contact dopamine D1 and D2 receptors, alfa1, alfa2 and beta adrenoceptors, histamine H1 receptors, gammaaminoglobulinovy acid (GAMK) – and benzodiazepine receptors, muskarinovy cholinergic receptors. Promotes improvement of mood, stops feeling of alarm, reduces sensation of fear and tension, eliminates a dysphoria, reduces persuasive states, practically does not cause sedation, the lasting clinical effect develops in 7-10 days of regular administration of drug. In very small degree inhibits an isoenzyme of P450 IID6 cytochrome therefore does not interact with medicines. Tsitol does not influence the carrying-out system of heart and arterial blood pressure, hematologic indicators, function of a liver and kidneys, does not cause increase in body weight and does not strengthen effect of alcohol. At drug the teratogenic action, influence on reproductive function and perinatal development of posterity is not revealed. Tsitol has fast antidepressive effect. The effect is shown on the second week of therapy, faster in comparison with fluoksitony, sertraline. Active action, both on a depression, and on alarm. Two problems – one decision.
– treatment of a depression and prevention of a recurrence
– treatment of panic disorder with or without agoraphobia
– treatment of a syndrome of persuasive states
the Route of administration and doses
by the Adult inside, washing down with a small amount of liquid, once at any time regardless of meal.
Therapy by Tsitol is begun in a daily dose of 10 – 20 mg in the morning, further the daily dose is increased if necessary to 40 mg a day depending on individual reaction of the patient and weight of a depression. The maximum single dose of 40 mg a day. According to individual reaction of the patient and degree of manifestation of a depression, the dose can be increased to the maximum 60 mg/days.
To patients of advanced age (65 years are more senior) the recommended daily dose makes 20 mg. Depending on individual reaction of the patient and degree of manifestation of degree of manifestation of a depression, the dose can be increased to maximum – 40 mg a day. In a liver failure the administration of drug should be limited to the minimum recommended doses.
In a small and moderate renal failure the correction of the mode of dosing is not required.
Therapy duration (for prevention of a recurrence) is of 6 months and more. Drug does not cause accustoming, at therapy by Tsitol the withdrawal is practically not registered.
– dryness in a mouth
– the increased sweating
the Contraindication tremor
– simultaneous use with MAO inhibitors (monoaminooxidase)
– hypersensitivity to a tsitalopram and other components
– children’s and teenage age up to 18 years (in view of lack of data on
safety and efficiency)
it is not necessary to use Drug in combination with monoaminooxidase inhibitors and also within 14 days after the termination of their reception.
Tsitol’s interaction with alcohol is not revealed.
Not established clinically significant pharmacokinetic interaction from fenotiazina and tricyclic antidepressants. Pharmakodinamichesky interaction of a tsitalopram and theophylline, benzodiazepines, neuroleptics, analgetik, lithium, anti-histamine, antihypertensive drugs, beta-blockers and other kardiotropny drugs is not revealed.
instructions Pregnancy and a lactation
Use of drug in a depression at pregnant women and in the period of a lactation (breastfeeding) is possible if the potential clinical advantage for mother exceeds potential risk for a fruit and the child.
Features of influence of medicine on ability to run motor transport or potentially dangerous
Tsitol mechanisms should be applied with care at persons whose activity is connected with mechanisms or management of moving means.
Tsitol does not reduce mental abilities.
Symptoms: drowsiness, moderate sinus tachycardia, the increased sweating, nausea. The clinical picture is not characteristic.
Treatment is symptomatic.
The form of release and packing
of the Tablet film coated in blister strip packaging on 14 tablets. On 2 or 4 blister strip packagings with the instruction for medical use in the Russian and state languages in a cardboard pack.
To Store storage conditions in dry, protected from light, the place, at
a temperature below 250 S. Hranit in places inaccessible for children!
not to apply a period of storage after the expiration date specified on packing!
According to the prescription
‘ABDI IBRAHIM Ilatsch Saneii Ve Tidzharet Anonim Shirketi’ Producer
of Reshitpash the Move., Eski Buyukdere of Dzhaddesi, No. 4, Maslak,
34467, Istanbul Turkey
Ph. + 90 (212) 354 18 00
Fax: + 90 (212) 286 10 37
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods) Representative office ‘ABDI IBRAHIM Ilatsch Saneii ve Tidzharet Anonim Shirketi’ in Kazakhstan, Almaty, the ave. of Abay 155, office 37/38,
ph. +7 (727) 394-35-12
fax: +7 (727) 295-29-35